Verition Fund Management
NGM

Verition Fund Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Verition Fund Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-45,739
Closed -$902K – 2397
2021
Q2 		$902K Sell
45,739
-70,987
-61% -$1.66M 0.01% 845
2021
Q1 		$3.39M Sell
116,726
-48,902
-30% -$1.37M 0.04% 275
2020
Q4 		$5.02M Buy
+165,628
New +$3.62M 0.04% 201

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Verition Fund Management's NGM Position: Q3 2021 in Review

Verition Fund Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2021, closing a stake of 45,739 shares — an estimated $902K sold.

Verition Fund Management first reported a position in NGM in Q4 2020 and held it in 3 quarters. The position peaked at $5.02M in Q4 2020. 120 funds tracked by Wall St. Rank hold NGM as of Q3 2021.

  • Verition Fund Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Verition Fund Management sold 45,739 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $902K.
  • Verition Fund Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Verition Fund Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $5.02M in Q4 2020.
  • 120 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Verition Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.